Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards

Disease

Therapeutic or Technology

Disease	Cell Type	Therapeutic or Technology	Institution	Project Objective
Beta Thalassemia	Adult Stem Cell	Gene-modified, personalized cell therapy	Sangamo	Clinical Trial, Phase 1 or Phase 1/2
Autism	iPS Cell	Small molecule therapy	Scripps	Development Candidate, Proof of Concept
COVID-19	iPS Cell	Small molecule therapy	Scripps	Development Candidate, Proof of Concept
Immune Disease, Severe Combined Immunodeficiency, X-linked (X-SCID)	Adult Stem Cell	Gene-modified, personalized cell therapy	St. Jude	Clinical Trial, Phase 1 or Phase 1/2
IPEX Syndrome, Immune Disease		Gene Therapy, cell free	Stanford	IND
Stroke	Embryonic Stem Cell	Donor cell therapy	Stanford	IND
COVID-19	Adult Stem Cell	Small molecule therapy	Stanford	Development Candidate, Proof of Concept
Epidermolysis Bullosa	iPS Cell	Gene-modified, personalized cell therapy	Stanford	Pre-IND/IDE or Equivalent
Thymic Disorder, 22q11 Deletion/DiGeorge	Embryonic Stem Cell, iPS Cell	Donor cell therapy	Stanford	Development Candidate, Proof of Concept
COVID-19	Adult Stem Cell	Vaccine	Stanford	Development Candidate, Proof of Concept
Blood Disorders	iPS Cell	Model system development	Stanford	Research Insights, Tool/Resources/Bottleneck
Kidney Failure	Adult Stem Cell	Donor cell therapy	Stanford	Clinical Trial, Phase 1 or Phase 1/2
Severe Combined Immunodeficiency, X-linked (X-SCID)	Adult Stem Cell	Antibody	Stanford	Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Leukemia	Adult Stem Cell	Gene-modified, personalized cell therapy	Stanford	Clinical Trial, Phase 1 or Phase 1/2
Kidney Failure	Adult Stem Cell	Donor cell therapy	Stanford	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	Stanford	IND
Bladder or Urinary Tract Disorder, Solid Tumors	Embryonic Stem Cell	Donor cell therapy	Stanford	Development Candidate, Proof of Concept
Skeletal/Smooth Muscle disorders	Adult Stem Cell	Protein/peptide therapy	Stanford	Research Insights
Skeletal/Smooth Muscle disorders	Adult Stem Cell	Small molecule therapy	Stanford	Development Candidate
Bladder or Urinary Tract Disorder, Incontinence	iPS Cell	Personalized cell therapy	Stanford	Pre-IND/IDE or Equivalent
Liver Disease	Embryonic Stem Cell	Donor cell therapy	Stanford	Development Candidate, Proof of Concept
Hearing Loss	Adult Stem Cell	Protein/peptide therapy	Stanford	Development Candidate, Proof of Concept
Heart Disease	iPS Cell	Donor cell therapy	Stanford	Development Candidate, Proof of Concept
Age-related macular degeneration	Adult Stem Cell	Donor cell therapy	Stanford	Pre-IND/IDE or Equivalent
Other	Embryonic Stem Cell	Cell imaging & tracking	UC Berkeley	Tool/Resources/Bottleneck
Spina Bifida	Adult Stem Cell	Donor cell therapy	UC Davis	IND
Osteonecrosis	Adult Stem Cell	Small molecule therapy	UC Davis	Clinical Trial, Phase 1 or Phase 1/2
HIV-related Lymphoma, HIV/AIDS	Adult Stem Cell	Gene-modified, personalized cell therapy	UC Davis	Clinical Trial, Phase 1 or Phase 1/2
Heart Disease	iPS Cell	Personalized cell therapy	UC Davis	Proof of Concept
Spinal Cord Injury	Adult Stem Cell	Donor cell therapy	UC Irvine	Development Candidate
Huntington's Disease	Embryonic Stem Cell	Donor cell therapy	UC Irvine	IND
Retinitis Pigmentosa	Embryonic Stem Cell	Donor cell therapy	UC Irvine	Pre-IND/IDE or Equivalent
Traumatic Brain Injury	Embryonic Stem Cell	Donor cell therapy	UC Irvine	Pre-IND/IDE or Equivalent
Neurological Disorders, Zika virus	Adult Stem Cell, iPS Cell	Vaccine	UCLA	Development Candidate
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage	Adult Stem Cell	Personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Cancer	Adult Stem Cell	Gene-modified, donor cell therapy	UCLA	Development Candidate, Proof of Concept
Corneal Damage	Adult Stem Cell	Personalized cell therapy	UCLA	IND
COVID-19	Adult Stem Cell	Vaccine	UCLA	Development Candidate, Proof of Concept
Hyper IgM Syndrome, Immune Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Pre-IND/IDE or Equivalent
Bone or Cartilage Disease	Adult Stem Cell	Donor cell therapy	UCLA	Proof of Concept
Multiple Myeloma	Adult Stem Cell	Personalized cell therapy	UCLA	Pre-IND/IDE or Equivalent
Sarcoma	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Lung Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Immune Disease, X-linked Chronic Granulomatous Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
COVID-19, Respiratory Disorders	iPS Cell	Small molecule therapy	UCLA	Development Candidate, Proof of Concept
Blood Disorders, Leukemia	Adult Stem Cell	Exploring stem cell mechanisms	UCLA	Development Candidate, Proof of Concept, Research Insights
COVID-19, Respiratory Disorders	Adult Stem Cell	Model system development	UCLA	Development Candidate, Proof of Concept, Tool/Resources/Bottleneck
Muscular Dystrophy	Embryonic Stem Cell, iPS Cell	Personalized cell therapy	UCLA	Development Candidate
Stroke	iPS Cell	Donor cell therapy	UCLA	Development Candidate

California's Stem Cell Agency

California Institute for Regenerative Medicine

Active Awards Portfolio Dashboard

Filter Awards

Pages

aa Multiple Diseases (Centers & Resoures)
Aging
Arthritis
Blood Disorders
– Alpha Thalassemia Major
– Anemia
– Beta Thalassemia
– Bone Marrow Transplant and Viral Infection
– Hemophilia A
– Hyper IgM Syndrome
– IPEX Syndrome
– Leukocyte Adhesion Deficiency
– Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
– Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
– Severe Combined Immunodeficiency, X-linked (X-SCID)
– Sickle Cell Disease
– X-linked Chronic Granulomatous Disease
Bone or Cartilage Disease
– Intervertebral disc degeneration
– Osteoarthritis
– Osteonecrosis
Cancer
– Blood Cancer
–– Acute Myeloid Leukemia
–– B cell cancers
–– HIV-related Lymphoma
–– Leukemia
–– Leukemia, Acute Myeloid (AML)
–– Multiple Myeloma
– Solid Tumors
–– Brain Cancer
–– Breast Cancer
–– Colon Cancer
–– Lung Cancer
–– Melanoma
–– Ovarian Cancer
–– Pancreatic Cancer
–– Prostate Cancer
–– Sarcoma
–– Skin cancer
Developmental Disorders
Fertility
Genetic Disorder
Hearing Loss
Heart Disease
– Heart disease associated with Duchenne muscular dystrophy
– Heart failure
– Pulmonary Hypertension
Immune Disease
– Thymic Disorder, 22q11 Deletion/DiGeorge
Incontinence
Infectious Disease
– COVID-19
– HIV/AIDS
– Zika virus
Kidney Disease
– Kidney Failure
Metabolic Disorders
– Cystinosis
– Danon Disease
– Diabetes
–– Diabetic Wounds
–– Type 1 diabetes
– Intestinal Disease
– Liver Disease
Multiple Indications (Alpha Clinics)
Neurological Disorders
– Alzheimer's Disease
– Amyotrophic Lateral Sclerosis
– Autism
– Brain Injury, hypoxic, ischemic
– Canavan Disease
– Dementia
– Epilepsy
– Huntington's Disease
– Multiple Sclerosis
– Neuropathy
– Parkinson's Disease
– Rett's Syndrome
– Spina Bifida
– Spinal Cord Injury
– Spinal Muscular Atrophy
– Stroke
– Traumatic Brain Injury
Other
Pediatrics
Respiratory Disorders
– Cystic Fibrosis
– Lung Disease, Fibrosis
Skeletal/Smooth Muscle disorders
– Bladder or Urinary Tract Disorder
– Muscular Dystrophy
Skin Disease
– Epidermolysis Bullosa
Toxicity
Trauma
Vascular Disease
Vision Loss
– Age-related macular degeneration
– Corneal Damage
– Retinitis Pigmentosa

Therapeutic Approach
– Biologic
–– Antibody
–– Convalescent Plasma
–– Exosomes based therapy
–– Gene modification
–– Nucleic acid based therapy
–– Protein/peptide therapy
–– Vaccine
– Gene Therapy (All)
–– Gene Therapy, cell free
–– Gene-modified, donor cell therapy
–– Gene-modified, personalized cell therapy
– Small molecule therapy
– Device
– Donor cell therapy
– Personalized cell therapy
– Other Components
Technology
– Assay development
– Cell Line Generation-Resource
– Diagnostic Test
– Gene editing tools
– Cell delivery or targeting
– Cell imaging & tracking
– Cell processing & handling
– Exploring disease mechanisms
– Exploring stem cell mechanisms
– Immune tolerance/management
– Model system development
– Specific Cell Type Derivation
– Therapeutic target discovery
– Tissue engineering